Genpharm and Apellis Pharmaceuticals Enter in an Exclusive Agreement
Dubai, March 1st 2023
Genpharm is pleased to announce it has entered into an exclusive agreement with Apellis Pharmaceuticals, Inc. to market and sell intravitreal pegcetacoplan upon regulatory approval in United Arab Emirates (UAE), Saudi Arabia, Oman, Qatar, Kuwait, and Bahrain. The FDA recently approved intravitreal pegcetacoplan in the United States for the treatment of geographic atrophy (GA), an advanced stage of age-related macular degeneration. GA is an irreversible disease that impacts approximately five million patients worldwide and a leading cause of blindness.
“We continue to build our strategic partnerships with our core mission in mind,” say Karim Smaira and Kamel Ghammachi the co-founders and managing partners of Genpharm. “Our mission is to facilitate access to the latest therapeutic innovations for patients in the MENA region, and intravitreal pegcetacoplan provides us with an opportunity to do so upon regulatory approval. We look forward to working closely with the ophthalmology community in the GCC to raise awareness and support them in their management of GA”.
About Apellis Pharmceuticals